Fig. 1

a LDL-C ± 1 SD calculated by Friedewald formula (mmol/l, black line ± 1 SD blue shadowing) and the amount of statin users (%, red line) at postoperative visits. b Plasma correlation of apoB ± 1 SD (g/l, black line ± 1 SD blue shadowing) and daily statin dose index (DSDI, black line ± 1 SD red shadowing) (see Methods) at postoperative visits. Red arrows indicate the publication of landmark studies from left to right: 4S³, CARE⁴, LIPID⁵, REVERSAL⁶ and PROVE IT⁸. Blue arrows refer to the publication of lipid lowering recommendations from left to right: Second European Task Force¹¹, NCEP ATP III¹², Third European Task force¹³, NCEP ATP III (Implication of recent clinical trials)¹⁴, and Fourth European Task Force¹⁵. Black arrows indicate the years, when the two most effective statins entered the Finnish market, i.e. atorvastatin in 1997 and rosuvastatin in 2003. LDL-C was calculated by Friedewald formula and apoB was obtained using extended Friedewald approach (see Methods)